S
Stephen W. Fesik
Researcher at Vanderbilt University
Publications - 298
Citations - 42613
Stephen W. Fesik is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Nuclear magnetic resonance spectroscopy & Binding site. The author has an hindex of 95, co-authored 294 publications receiving 40006 citations. Previous affiliations of Stephen W. Fesik include Howard Hughes Medical Institute & Yale University.
Papers
More filters
Journal ArticleDOI
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf,Steven W. Elmore,Alexander R. Shoemaker,Robert C. Armstrong,David J. Augeri,Barbara A. Belli,Milan Bruncko,Thomas L. Deckwerth,Jürgen Dinges,Philip J. Hajduk,Mary K. Joseph,Shinichi Kitada,Stanley J. Korsmeyer,Stanley J. Korsmeyer,Kunzer Aaron R,Anthony Letai,Chi Li,Michael J. Mitten,David G. Nettesheim,Shi Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Anatol Oleksijew,Andrew M. Petros,John C. Reed,Wang Shen,Stephen K. Tahir,Craig B. Thompson,Kevin J. Tomaselli,Baole Wang,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg +33 more
TL;DR: Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.
Journal ArticleDOI
Discovering High-Affinity Ligands for Proteins: SAR by NMR
TL;DR: A nuclear magnetic resonance (NMR)-based method is described in which small organic molecules that bind to proximal subsites of a protein are identified, optimized, and linked together to produce high-affinity ligands and appears particularly useful in target-directed drug research.
Journal ArticleDOI
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa R. Roberts,Stephen K. Tahir,Yu Xiao,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +17 more
TL;DR: The biological properties and rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies are provided and the oral efficacy should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens are reported.
Journal ArticleDOI
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Michael Sattler,Heng Liang,David G. Nettesheim,Robert P. Meadows,John E. Harlan,Matthias Eberstadt,Ho Sup Yoon,Suzanne B. Shuker,Brian S. Chang,Andy J. Minn,Craig B. Thompson,Stephen W. Fesik +11 more
TL;DR: The structure and binding affinities of mutant Bak peptides indicate that the Bak peptide adopts an amphipathic α helix that interacts with Bcl-xL through hydrophobic and electrostatic interactions.
Journal ArticleDOI
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death.
Steven W. Muchmore,Michael Sattler,Heng Liang,Robert P. Meadows,John E. Harlan,Ho Sup Yoon,David G. Nettesheim,Brian S. Chang,Brian S. Chang,Craig B. Thompson,Craig B. Thompson,Sui-Lam Wong,Shi-Chung Ng,Stephen W. Fesik +13 more
TL;DR: The arrangement of the α-helices in Bcl-xL is reminiscent of the membrane translocation domain of bacterial toxins, in particular diphia toxin and the colicins, and may provide a clue to the mechanism of action of the B cl-2 family of proteins.